Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 243
  • Print this page
  • Email this page

 
Table of Contents
ORIGINAL ARTICLE
Year : 2022  |  Volume : 15  |  Issue : 2  |  Page : 56-62

Patterns of adverse drug reaction reporting in Ethiopia: A database analysis of spontaneous reports from 2013 to 2018


Department of Pharmacology, Faculty of Pharmacy, Near East University, Nicosia, T.R.N.C, Cyprus, Turkey

Date of Submission21-Dec-2021
Date of Decision20-Feb-2022
Date of Acceptance22-Feb-2022
Date of Web Publication28-Feb-2022

Correspondence Address:
Nurrettin Abacioglu
Department of Pharmacology, Faculty of Pharmacy, Near East University, Nicosia, T.R.N.C, Cyprus
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.338436

Rights and Permissions
  Abstract 


Objective: To examine the frequency and profile of spontaneous reports of adverse drug reactions (ADRs) sent to Ethiopia’s pharmacovigilance (PV) database system.
Methods: The descriptive and retrospective study analysed spontaneous ADR complaints reported to the PV database by healthcare professionals between 2013 and 2018. Spontaneous ADR reports that reached the PV center and met the minimum reporting criteria were identified and assessed in terms of reporting rate, patient characteristics, type of ADRs, suspected drugs, report sources, and reporters’ profession.
Results: A total of 657 spontaneous ADR reports were filed to the PV center between 2013 and 2018. During the study period, the reporting pattern of ADRs changed dramatically. The number of reports increased from 2013 (n=12) and peaked in 2015 (n=205), and then declined from 2016 to 2018 (n=144, 142 and 65 in 2016, 2017 and 2018, respectively). Females had a higher percentage of reported cases (56.3%) than males (43.7%). The highest number of ADRs was reported in the age categories of 15-64 years (475, 72.3%), followed by 0-14 years (154, 23.4%), and 65 years and above (21, 3.2%). Pharmacists reported the majority of ADRs (81.7%), followed by health officers (7.2%), nurses (5.8%), and physicians (5.2%). Skin and subcutaneous tissue abnormalities were the most commonly reported ADRs. The anatomical therapeutic chemicals code class “anti-infective for systemic use” was the most usually suspected medication. Trimethoprim with sulfamethoxazole as a combination ADRs was the most commonly reported drug that cause ADRs (14.2%).
Conclusions: The number of ADRs reported in Ethiopia was small and unpredictable compared to developed countries, indicating the performance of PV system and level of awareness of health care professionals towards ADR reporting was not satisfactory. In order to increase the frequency of spontaneous reports, more efficient PV methods and public policies must be implemented.

Keywords: Pharmacovigilance; Adverse drug reactions; Spontaneous report


How to cite this article:
Anebo ZG, Abacioglu N. Patterns of adverse drug reaction reporting in Ethiopia: A database analysis of spontaneous reports from 2013 to 2018. Asian Pac J Trop Med 2022;15:56-62

How to cite this URL:
Anebo ZG, Abacioglu N. Patterns of adverse drug reaction reporting in Ethiopia: A database analysis of spontaneous reports from 2013 to 2018. Asian Pac J Trop Med [serial online] 2022 [cited 2022 Dec 5];15:56-62. Available from: https://www.apjtm.org/text.asp?2022/15/2/56/338436




  1. Introduction Top


Adverse drug reactions (ADRs), which are one of the top causes of morbidity and mortality globally, will continue to be a public health issue if medicines are used to treat a variety of conditions[1]. According to the World Health Organization, adverse drug reactions (ADRs) is “any unpleasant and unanticipated reaction to a drug that could occur at levels utilized for prevention, diagnosis, or therapy”[2].



In Ethiopia, only a few studies have been undertaken to analyze health care professionals’ knowledge, attitude, and practice regarding ADRs reporting. These findings revealed that health care professionals have a good attitude toward ADRs reporting but insufficient knowledge and practice[3],[4]. Ermias et al.[3] found that the degree of ADRs case reporting in Ethiopia is relatively low, based on a review of case reports from 2002 to 2007. In Ethiopia, there is a scarcity of data on healthcare personnel’s knowledge, attitudes, and practices concerning ADRs reporting at the health facility level[4]. As a result, the goal of this study was to examine the national ADR reports that were filed to the pharmacovigilance (PV) center during 2013-2018.


  2. Materials and methods Top


2.1. Data source

Between 2013 and 2018, the national ADRs data reports trends for all marketed drugs reported to the PV database center were evaluated. Spontaneous ADR reports that reached the PV center and met the minimum reporting criteria were identified and assessed in terms of reporting rate, patient characteristics, type of ADRs, suspected drugs, report sources, and reporters’ profession according to the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E2A criteria used in VigiBase[6]. Patient support program ADR reports, research cases, case reports, and follow-up reports were all eliminated. Furthermore, more than one suspect drug and/or ADR could be included in a single report.

The database was used to extract information about the patient’s characteristics (age and sex), the reporter’s qualifications, suspected drugs, ADRs, and the severity of the ADRs for each ADR report. Healthcare professionals, such as physicians, pharmacists, nurses, health officers, and midwives, were classed as reporters of ADRs.

There were three age groups included in this study. Patients were split into pediatric (0-14 years old), adults (15-64 years old), and geriatric (65 and above years old)[7]. The anatomical ttherapeutic chemical (ATC) cclassification system one level was used to classify suspected drugs[8].

The Medical Dictionary for Regulatory Activities was used to code ADRs, which were extracted from source data using system organ classifications and preferred terms[9].

2.2. Statistical analysis

Descriptive statistics were performed based on ADRs as counts and percentages. ADR reports were analyzed based on demographic characteristics (age and gender), geographical area or location from which they were reported, involved body system as defined by the system organ classifications, time of occurrence, health professional who reported cases, drug implicated, and ADR manifestations.


  3. Results Top


The study examined all of the marketed drugs’ spontaneous ADRs reports that were reported to the PV center between 2013 and 2018. During the study period, 657 spontaneous reports met the reporting minimum criteria and were thus included in the analysis.

3.1. Trends in ADR reporting

The number of reports in 2013 was 12, which peaked in 2015 (n=205), and then began to decline between 2016 and 2018 (144, 142 and 65, respectively) [Figure 1].
Figure 1: The annual numbers of spontaneous adverse drug reactions reports submitted to Ethiopia’s pharmacovigilance center between 2013 and 2018.

Click here to view


3.2. ADRs by sex

In terms of patient gender, females were reported in 370 (56.3%) of reports, while men were reported in 287 (43.7%) of reports. Females reported a higher percentage of incidents than males.

3.3. ADRs by age

To observe the trend of reporting with respect to age groupings, ADRs by age were estimated in three categorical age groups. The highest number of ADRs were reported in the age category of 15-64 years (475, 72.3%), followed by 0-14 years (154, 23.4%), and 65 years and above (21, 3.2%). A tiny percentage of reports (7, 1.0%) neglected to mention the age category.

3.4. Qualification of reporters

During 2013 and 2018, pharmacists reported the majority of ADRs (81.7%), followed by health officers (7.2%), nurses (5.8%), nurses (5.8%) and physicians (5.2%). Midwifery (0.2%) reported a small proportion of reports [Table 1].
Table 1: The pattern of spontaneous adverse drug reactions reporting by health care professionals in Ethiopia from 2013-2018.

Click here to view


3.5. ADRs for different therapeutic groups

The first ATC code levels were used to analyze suspected drugs mentioned in ADRs reports. The ATC level classes “anti-infective for systemic use” (78.6%), “antiparasitic products, insecticides, and repellants” (4.8%), “alimentary tract and metabolism” (3.6%), and “nervous system” (3.6%) are the most commonly reported ATC classes of drugs. These ATC classes were the most commonly reported drug groups throughout all years studied. “Antibacterial for systemic use” and “antivirals for systemic use” are the two main product groups implicated in “ant infective for systemic use” [Figure 2].
Figure 2: Percentage distribution of adverse drug reactions reports by anatomical therapeutic chemical class (first level) of suspected drugs between 2013-2018.

Click here to view


Trimethoprim and sulfamethoxazole have the highest number of ADRs (14.2%), followed by amoxicillin (10.5%), zidovudine, lamivudine, and nevirapine (6.7%), and ciprofloxacin (5.5%) [Table 2].
Table 2: Top 10 drug lists and their respective therapeutic classes related to the adverse drug reactions rreports by health care professionals during 2013-2018 (n=657).

Click here to view


3.6. ADRs by system organ classification

The most commonly reported ADR system organ classification in the database are skin and subcutaneous tissue disorders (437, 66.5%), gastrointestinal disorders (47, 7.2%), blood and lymphatic system problems (40, 6.1%), and nervous system illness (28, 4.3%). [Figure 3] depicts the most often reported terms during the study period. Rashes (220, 33.5%), itching (76, 11.6%), anemia (51, 7.8%), allergy (47, 7.2%), and vomiting (30, 4.6%) were the most commonly reported phrases by healthcare professionals.
Figure 3: The most frequent preferred terms in adverse drug reactions reports by healthcare professionals.

Click here to view


3.7. ADR report by location

The capital Addis Ababa reported 353 (53.7%) of the ADR reports, followed by the Amhara area 142 (21.6%), Oromia 59 (9.0%), Snnpr 46 (7.0%), Tigray 40 (6.1%), Afar 14 (2.1%), Dire Dawa 2 (0.3%), and Harar 1 (0.2%). During the data collection period for this study, no reports were recorded in the remaining regions [Figure 4].
Figure 4: The number of cases of adverse drug reactions reports from different regions in Ethiopia 2013 to 2018.

Click here to view


3.8. ADR out come at the time of reporting

At the time of reporting, the majority of patients (430, 65.4%) had recovered without sequela. However, 18 (2.7%) cases were found with sequela, 58 (8.8%) had not yet been recovered, and 8 (1.2%) died (drug may be contributory) and 143 (21.8%) were unknown outcome.


  4. Discussion Top


The goal of this study was to examine the trends of spontaneous ADR reporting in Ethiopia’s national PV database. During the study period, the ADRs profile in the country revealed a fluctuating pattern. Between 2013 and 2015, there was the greatest increase, however, between 2016 and 2018, there was a considerable reduction. Despite the fact that the number of ADRs reported in Ethiopia was low and fluctuating in comparison to that in industrialized countries, it nevertheless shows an increased tendency, indicating that the health care professionals are becoming more aware of PV system in Ethiopia which was established under Food, Medicines and Healthcare Administration and Control Authority in 2002. In 2008, Ethiopia became an official member of the World Health Organization Program for International Drug Monitoring[10] and voluntary reporting has been effective as in 2010[11]. Since the establishment of the PV system, the number of ADR reports received from health care professionals is limited in numbers[12]. The low level of ADRs reporting in this study can be linked to a variety of reasons, including insufficient HCP training, a lack of reporting tools, limited utilization and poor feedback on ADRs surveillance reports, and low coverage/poor integration at health facilities[3].

During 2013 and 2018, ADRs reported in female patients (56.3%) were substantially higher than those reported in male patients (43.7%). This is in line with earlier research that have found that females are more likely than males to develop ADRs[10],[11],[12]. Males, on the other hand, had a higher risk of ADR than females, according to studies by Sriram et al., and Richa et al[13],[14]. The higher prevalence of reporting among females could be due to a variety of factors. ADR occurrence is affected by a variety of factors such as patient age, gender, number of drugs taken, length of hospital stay, genetic factors, ethnicity, dietary, and environmental factors[13]. Female patients may have a higher frequency of ADRs, and they may also consult health care practitioners about ADRs more frequently[14].

Most number of ADRs reported was in the 15-64 year old age group (72.3%) which was much higher than those for the other age groups of pediatric and geriatric populations. Multi-drug therapy or other disorders such as hypertension, diabetes, asthma, or other chronic diseases may be the cause of excessive morbidity in the adult population. Our findings are similar with the finding of Adimasu et al[12],[15].

Only a few (3.2%) reports were received from those aged 65 and above. This is supported by other studies. Geriatric ADR was reported at a rate of 4.3% in a study by Amin et al[20] also, similar results indicated by Sriram et al[16]. Despite the fact that patients in the geriatric age group are particularly prone to adverse drug reactions, the minimal number of ADRs reports received indicates that this group has gotten inadequate attention[17].

For the years 2013-2018, it was observed that pharmacists reported more ADRs than physicians, health officers, and nurses. This rise in ADR reports among pharmacists could be explained by Ethiopia’s recent shift in pharmacy practice from product-oriented to patient- focused clinical pharmacy practice[18].

Gurmesa and Dedefo[19] compared health care preofessionals’ understanding of ADR reporting, finding that physicians and pharmacists were more aware of ADR than health care officers and nurses. Another study found that nurses, health care officials, and physicians were 93.1% less likely than pharmacy professionals to have adequate knowledge of ADR reporting.

Skin and subcutaneous tissue diseases (66.5%), gastrointestinal disorders (7.2%), blood and lymphatic system disorders (6.1%), and nervous system disorders (4.3%) were the most frequently reported ADRs among SOCs for ADRs. This pattern differs from the global pattern of ADRs from 2000 to 2009, when the most often reported SOCs for ADRs were general disorders and administrative site problems, skin and subcutaneous tissue disorders, and GIT disorders[20]. On the other hand this study is consistent with other studies by Coelho et al[24] Tripathy et al[25] and Patidar et al[17] but it differs from reports of Asiama et al[26] where gastrointestinal manifestations had the highest rate, which was second highest in our study (7.2%).

Suspect drugs mentioned in ADR reports were investigated at the ATC level 1. The drugs suspected of being linked to an ADR most frequently reported by health care professionals belong to the classes “anti-infective for systemic use” (78.6%), “antiphrastic products, insecticides and repellants” (4.8%), “aalimentary tract and metabolism” (3.6%), and “nervous system” (3.6%) at the first ATC level. This is similar to the patterns of ADRs observed by Aagaard et al[20] in upper middle-income countries, where drugs from the ATC class of anti-infective for systemic (24.5%) showed high rates of reporting. However, antineoplastic and immune modulating medicines accounted for 26.5% of all ATC drugs reported in Turkey[14]; although it was the eight most common ATC groups in the upper middle-income countries[20]. “Antibacterial for systemic use” and “antivirals for systemic use (dominated by antiretroviral)” are the main therapy groups implicated in “anti-infective for systemic use” in this study. The domination of antiretroviral products in African ADRs is perhaps not surprising considering the high burden of HIV/AIDS on the continent. With well-funded programmes providing access to antiretroviral, it is expected that there would be more ADRs on these products since healthcare workers in these programmes tend to be trained about PV system. Indeed, most published PV studies from Africa tend to be on the safety of antiretroviral[22].

Drugs from the “anti-infective for systemic use”, “gastrointestinal tract and metabolism”, and “nervous system” classes are among the most widely used in Ethiopia, therefore it’s no surprise that they were among the most commonly reported drugs at the first ATC level. Our findings resemble another study on this topic by Aagaard et al[23].

Trimethoprim plus sulfamethoxazole (14.2%) is the most prevalent drug that causes ADR, followed by amoxicillin (10.5%) and zidovudine, lamivudine, and nevirapine (6.7%). It’s possible that the high reporting rate for these therapeutic groups is due to higher drug consumption. Furthermore, most of these agents cause immediate and easily observable reactions that are classified as skin and subcutaneous tissue disorders, general disorders, and administration site conditions, for which causality between the drug and the reaction can be established quickly. This result is inconsistent with other studies in Turkey where adalimumab was the most commonly reported active substances by Fattinger et al[14], and Rivaroxaban by Graan et al[24] respectively.

This study examined only at spontaneous reports received to a national database between 2013 and 2018, which is similar to study by Aaagard et al[20] who analyzed spontaneous reports submitted to VigiBase from 2000 to 2009. Antiretroviral and antibiotics are the main product classes implicated in ADRs, according to Ampadu et al[22], who examined spontaneous ADRs characteristics between Africa and the rest of the world using Vigibase data.

The drug classes associated in ADRs from Africa differ from those from the rest of the globe. Disparities in disease patterns and prescriptions, variances in PV systems and ADR reporting, and differences in health systems and health literacy, to name a few, could all have a role[22]. Rajesh et al[12], Desai et al[17], Leone et al[26], reported that antibiotics are the most common classes causing ADRs which is similar in our study patients on anti- infective for systemic use had maximum ADRs. Trimethoprim and sulfamethoxazole were the most common drugs to cause ADRs (14.2%), followed by amoxicillin (10.5%), zidovudine, lamivudine, and nevirapine (3.8%), and ciprofloxacin (5.5%). It is because of increased consumption of anti-infective for systemic use for long duration as compared to other classes of drugs.

Despite the fact that the number of ADRs recorded in Ethiopia were few and unpredictable in comparison to that in developed nations, it nevertheless shows an upward trend, indicating that health care providers are becoming more aware of PV system. This study showed that more effective pharmacovigilance methods and public policies must be established in order to improve the number of spontaneous reports. To summarize, increasing the number of spontaneous reports and improving the quality of notifications, promoting active surveillance in hospitals, and conducting healthcare professional training are all important.

Data limitations in this study need to be addressed in the future to allow for more rigorous analysis and findings. Many ADR reports collected were excluded due to incomplete information. Nonetheless, our findings could help researchers develop hypotheses for future drug-event interactions research.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Acknowledgments

The authors gratefully acknowledge Ethiopian Food, Medicines and Health Administration and Control Authority (FMHACA) for ADR data collection and process inquiry.

Authors’ contributions

ZG collected and analyzed the data. NA provided technical assistance and oversaw the research. The final manuscript was read and approved by both authors.



 
  References Top

1.
Hadi MA, Neoh CF, Zin RM, Elrggal M, Cheema E. Pharmacovigilance: Pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract 2017; 6: 91-98.  Back to cited text no. 1
    
2.
WHO. International drug monitoring: The role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]. [Online]. Available from: https://apps.who.int/iris/handle/10665/40968. [Accessed on 21 December 2021].  Back to cited text no. 2
    
3.
Ermias A, Gurmesa G, Mesfin M, Mengistu A. Adverse drug reaction monitoring in Ethiopia: Analysis of case reports, 2002-2007. Ethiop J Heal Dev 2011; 25(2): 168-173.  Back to cited text no. 3
    
4.
Seid MA, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. Int J Clin Pharm 2018; 40(4): 895-902.  Back to cited text no. 4
    
5.
Mulatu WN, Worku A. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. J Pharmacovigil 2014; 2: 4.  Back to cited text no. 5
    
6.
ICH. ICH harmonised tripartite guideline clinical safety data m anagement: E2A. 1994. [Online]. Available from: https://www.ich.org/. [Accessed on 21 December 2021].  Back to cited text no. 6
    
7.
Wikipedia. Demographics of Ethiopia. [Online]. Available from: https:// en.wikipedia.org/wiki/. [Accessed on 21 December 2021].  Back to cited text no. 7
    
8.
WHO. Guidelines for ATC classification and DDD assignment. 2013. [Online]. Available from: https://www.whocc.no/filearchive/ publications/1_2013guidelines.pdf. [Accessed on 21 December 2021].  Back to cited text no. 8
    
9.
WHO. Introductory guide MedRA. 2011. [Online]. Available from: http://www.umc-products.com/graphics/28010.pdf. [Accessed on 21 December 2021].  Back to cited text no. 9
    
10.
Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: Analyses of spontaneous reports in VigiBase®. Drug Saf 2016; 39(4): 335-345.  Back to cited text no. 10
    
11.
Hailu AD, Mohammed SA. Adverse drug reaction reporting in Ethiopia: Systematic review. Biomed Res Int 2020; doi: https://doi. org/10.1155/2020/8569314.  Back to cited text no. 11
    
12.
Adimasu A. Nurses knowledge related to adverse drug reaction reporting and associated factors at Felegehiwot Referral Hospital and University of Gondar Teaching Hospital, Northwest Ethiopia. Am J Heal Res 2014; 2(4): 164.  Back to cited text no. 12
    
13.
Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK, et al. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci 2011; 16(1): 16-25.  Back to cited text no. 13
    
14.
Richa, Tandon V, Sharma S, Khajuria V, Mahajan V, Gillani Z. Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India. Indian J Med Microbiol 2015; 33(3): 393-400.  Back to cited text no. 14
    
15.
Saxena K, Tailor C, Mehta C, Gajera P, Srivastava SK. A retrospective analysis of adverse drug reaction reported in a tertiary care hospital. Int J Basic Clin Pharmacol 2017; 6(5): 1146.  Back to cited text no. 15
    
16.
Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse drug reaction reporting pattern in Turkey: Analysis of the national database in the context of the first pharmacovigilance legislation. Drugs-Real World Outcomes 2016; 3: 33-43.  Back to cited text no. 16
    
17.
Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscipl Toxicol 2013; 6(1): 41-46.  Back to cited text no. 17
    
18.
Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: The JADE study. J Gen Intern Med 2011; 26(2): 148-153.  Back to cited text no. 18
    
19.
Mandavi, D’Cruz S, Sachdev A, Tiwari P. Adverse drug reactions & their risk factors among Indian ambulatory elderly patients. Indian J Med Res 2012; 136(3): 404-410.  Back to cited text no. 19
    
20.
Amin S, Shah S, Desai M, Shah A, Maheriya KM, Saloni A, et al. An analysis of adverse drug reactions in extremes of age group at tertiary care teaching hospital. Perspect Clin Res 2018; 9(2): 70-75.  Back to cited text no. 20
    
21.
Mekonnen AB, Yesuf EA, Odegard PS, Wega SS. Pharmacists’ journey to clinical pharmacy practice in Ethiopia: Key informants’ perspective. SAGE Open Med 2013; doi: 10.1177/2050312113502959.  Back to cited text no. 21
    
22.
Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. Biomed Res Int 2016; 2016: 5-8.  Back to cited text no. 22
    
23.
Aagaard L, Strandell J, Melskens L, Petersen PSGG, Holme Hansen E. Global patterns of adverse drug reactions over a decade. Drug Saf 2012; 35(12): 1171-1182.  Back to cited text no. 23
    
24.
Santos DB, Coelho HLL. Adverse drug reactions in hospitalized children in Fortaleza, Brazil. Pharmacoepidemiol Drug Saf 2006; 15: 635-640.  Back to cited text no. 24
    
25.
Tripathy R, Das S, Das P, Mohakud NK, Das M. Adverse drug reactions in the pediatric population: Findings from the adverse drug reaction monitoring center of a teaching hospital in Odisha (2015-2020). Cureus 2021; 13(11): 9-15.  Back to cited text no. 25
    
26.
Asiamah M, Akuffo KO, Nortey P, Donkor N, Danso-Appiah A. Spontaneous reporting of adverse drug reaction among health professionals in Ghana. Arch Public Heal 2022; 80(1): 1-11.  Back to cited text no. 26
    
27.
Aydınkarahaliloğlu ND, Aykaç E, Atalan Ö, Demir N, Hayran M. Spontaneous reporting of adverse drug reactions by consumers in comparison with healthcare professionals in Turkey from 2014 to 2016. Pharmaceut Med 2018; 32(5): 353-364.  Back to cited text no. 27
    
28.
Conforti A, Opri S, D’Incau P, Sottosanti, Moretti U, Ferrazin F. Adverse drug reaction reporting by nurses: Analysis of Italian pharmacovigilance database. Pharmacoepidemiol Drug Saf 2017; 18: 172-178.  Back to cited text no. 28
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  2. Materials and...
  In this article
Abstract
1. Introduction
3. Results
4. Discussion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed1209    
    Printed38    
    Emailed2    
    PDF Downloaded219    
    Comments [Add]    

Recommend this journal